FDA Extends PDUFA Date for Priority Review of NDA for Salix Pharma's (SLXP) Crofelemer Tablets
Get Alerts SLXP Hot Sheet
Join SI Premium – FREE
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the U.S. FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for the Agency’s Priority Review of the New Drug Application (NDA) for Crofelemer 125 mg tablets for the proposed indication for the control and symptomatic relief of diarrhea in patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy (ART). The FDA has notified Salix that it requires additional time for a full review of the submission and has extended the June 5, 2012 goal date by three months. The extended user fee goal date is September 5, 2012. The FDA did not request additional studies.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PMV Pharmaceuticals (PMVP) PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO
- DLocal Limited (DLO) Appoints Mark Ortiz as New Chief Financial Officer
- Madrigal Pharma (MDGL) Announces Pricing of Upsized $600 Million Public Offering
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!